| Browse |
| Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants. |
| Lineage (WHO label)   | Target Gene | Primer Name | Primer Sequence | Primer Length | Primer GC Content (%) | Start Position | End Position | Primer Direction | ΔG (cal) | Primer first used |
|---|---|---|---|---|---|---|---|---|---|---|
| BF.7.13.2 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BF.37 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| CK.3 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| CM.5 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| XBC.1.3.1 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| JN.11.1 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| XDL | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -18526.8 | US |
| JN.17 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| AY.29.1 (Delta) | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| AY.29.2 (Delta) | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BC.1 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.2.10.1 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.2.3.1 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.2.3.13 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.2.3.9 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.2.10.2 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.2.56 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.2.29 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.2.10 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.2.51 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.2.3.18 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| XAT | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.2.24 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.2.12 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BM.3 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.5.2.28 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.5.2.62 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.5.2.24 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.5.8 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.2.13.1 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BF.28 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.5.1.1 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BE.1.1.1 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| XAZ | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BE.4 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.5.1.24 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.5.1.16 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.5.2.26 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.5.2.2 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BF.22 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.5.2.21 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.5.2.22 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BF.10 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BF.38 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.2.3.11 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.2.3.2 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.2.85 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.2.65 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BA.5.1.3 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| BG.5 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -18526.8 | US |
| Lineage (WHO label) | Target Gene | Primer Name | Primer Sequence | Primer Length | Primer GC Content (%) | Start Position | End Position | Primer Direction | ΔG (cal) | Primer first used |